Neostigmine
Neostigmine Bromide 15 mg
Company Name
MemphisTherapeutic Group
ALL OTHER CNS DRUGSPharmaceutical form
TabletPackage
Box containing 20 tabletsIndications
Neostigmine is indicated for the symptomatic treatment of myasthenia gravis.Warning & Precautions
Neostigmine should be used with caution: - in patients with epilepsy, bronchial asthma, bradycardia, hyperthyroidism, peptic ulcer, recent coronary occlusion, vagotonia and cardiac arrhythmias. - when administered with anticholinergic drugs, in order to avoid reduction of intestinal motility. -Pediatric use: Safety and effectiveness in children have not been established. -Either discontinue nursing or discontinue the drug taking into account the importance of the drug to the mother. -Neostigmine should be given to a pregnant woman only if clearly needed.Product Type
HumanDosage
Initial : 15 mg every 3 - 4 hours, the dose and frequency of administration being adjusted as necessary. Maintenance: 150 mg administered over a twenty-four hour period, the intervals between doses being determined by response of the patient.
Adverse Reactions
Some of the following side effects may occur in some cases: Salivation, allergic reactions, convulsions, cardiac arrhythmias, increased bronchial secretions, fasciculation, bowel cramps, diarrhea, anaphylaxis, loss of consciousness, drowsiness, headache, dysarthria, miosis and visual changes, rash, nausea, emesis, flatulence, increased peristalsis, urinary frequency, muscle cramps and spasms, arthralgia, diaphoresis, flushing and weakness.Contra Indications
Neostigmine is contraindicated in: -Patients with peritonitis or mechanical obstruction of the intestinal or urinary tract. -Patients with known hypersensitivity to the drugDrug Interactions
-Streptomycin, neomycin and kanamycin have a mild but definite non-depolarizing blocking action which may accentuate neuromuscular block. -Local and some general anesthetics and antiarrhythmic agents that interfere with neuromuscular transmission should be used cautiously
No comments:
Post a Comment